<i>Erratum</i> to: Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation

• Zachary D. Epstein-Peterson,
• Esther Drill,
• Umut Aypar,
• Connie Lee Batlevi,
• Philip Caron,
• Ahmet Dogan,
• Pamela Drullinsky,
• John Gerecitano,
• Paul A. Hamlin,
• Caleb Ho,
• Allison Jacob,
• Ashlee Joseph,
• Leana Laraque,
• Matthew J. Matasar,
• Alison J. Moskowitz,
• Craig H. Moskowitz,
• Chelsea Mullins,
• Colette Owens,
• Gilles Salles,
• Heiko Schöder,
• David J. Straus,
• Anas Younes,
• Andrew D. Zelenetz,
• Anita Kumar

Affiliations

Zachary D. Epstein-Peterson

Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

Esther Drill

Department of Biostatistics and Epidemiology, Memorial Sloan Kettering Cancer Center, New York, NY

Umut Aypar

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY

Connie Lee Batlevi

Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

Philip Caron

Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

Ahmet Dogan

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY

Pamela Drullinsky

Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

John Gerecitano

Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

Paul A. Hamlin

Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

Caleb Ho

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY

Allison Jacob

Adaptive Biotechnologies, Seattle, WA

Ashlee Joseph

Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

Leana Laraque

Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

Matthew J. Matasar

Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

Alison J. Moskowitz

Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

Craig H. Moskowitz

Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

Chelsea Mullins

Adaptive Biotechnologies, Seattle, WA

Colette Owens

Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

Gilles Salles

Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

Heiko Schöder

Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA

David J. Straus

Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

Anas Younes

Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

Andrew D. Zelenetz

Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

Anita Kumar

Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY